$GOVX
GeoVax Labs, Inc.

2015 Q4 Form 10-K Financial Statement

#000143774916027776 Filed on March 16, 2016

View on sec.gov

Income Statement

Concept 2015 Q4 2015 Q3 2015 Q2
Revenue $160.1K $93.13K $71.47K
YoY Change -28.26% -71.09% -60.39%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $330.0K $340.0K $360.0K
YoY Change -51.47% -17.07% 5.88%
% of Gross Profit
Research & Development $530.0K $378.5K $384.7K
YoY Change 12.77% -11.04% -25.48%
% of Gross Profit
Depreciation & Amortization $10.00K $10.00K $0.00
YoY Change -50.0% -50.0% -100.0%
% of Gross Profit
Operating Expenses $850.0K $714.5K $749.5K
YoY Change -26.09% -14.67% -12.95%
Operating Profit -$621.3K -$678.1K
YoY Change 20.59% -0.38%
Interest Expense $0.00 $0.00 $0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net $1.424K
YoY Change 100.28%
Pretax Income -$690.0K -$620.0K -$680.0K
YoY Change -25.0% 21.57% 0.0%
Income Tax
% Of Pretax Income
Net Earnings -$692.7K -$619.9K -$676.2K
YoY Change -25.0% 20.48% -0.49%
Net Earnings / Revenue -432.81% -665.63% -946.08%
Basic Earnings Per Share -$0.02 -$0.02 -$0.02
Diluted Earnings Per Share -$433.6B -$388.0B -$423.3B
COMMON SHARES
Basic Shares Outstanding 31.95M
Diluted Shares Outstanding

Balance Sheet

Concept 2015 Q4 2015 Q3 2015 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.060M $1.820M $2.480M
YoY Change -3.64% 111.63% 81.02%
Cash & Equivalents $1.060M $1.821M $2.476M
Short-Term Investments
Other Short-Term Assets $60.00K $80.00K $40.00K
YoY Change 50.0% 33.33% 33.33%
Inventory
Prepaid Expenses
Receivables $120.0K $0.00 $40.00K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $1.237M $1.896M $2.555M
YoY Change 0.94% 104.7% 82.49%
LONG-TERM ASSETS
Property, Plant & Equipment $83.61K $90.84K $98.08K
YoY Change -13.53% -19.77% -1.92%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $11.01K $10.00K $10.00K
YoY Change 0.0% -25.98% 0.0%
Total Long-Term Assets $94.62K $101.9K $109.1K
YoY Change -12.15% -19.64% -9.1%
TOTAL ASSETS
Total Short-Term Assets $1.237M $1.896M $2.555M
Total Long-Term Assets $94.62K $101.9K $109.1K
Total Assets $1.332M $1.998M $2.664M
YoY Change -0.12% 89.74% 75.26%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $100.9K $42.49K $111.0K
YoY Change 81.49% -48.3% -7.47%
Accrued Expenses $26.06K $5.000K $13.00K
YoY Change -50.36% -39.61% 30.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $127.0K $118.2K $181.1K
YoY Change -32.1% -30.55% -24.55%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $127.0K $118.2K $181.1K
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $130.0K $120.0K $180.0K
YoY Change -31.58% -29.41% -25.0%
SHAREHOLDERS EQUITY
Retained Earnings -$32.47M -$31.78M -$31.16M
YoY Change 9.03%
Common Stock $32.62M $32.60M $32.59M
YoY Change 5.72% 12.85%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $1.205M $1.880M $2.483M
YoY Change
Total Liabilities & Shareholders Equity $1.332M $1.998M $2.664M
YoY Change -0.12% 89.74% 75.26%

Cashflow Statement

Concept 2015 Q4 2015 Q3 2015 Q2
OPERATING ACTIVITIES
Net Income -$692.7K -$619.9K -$676.2K
YoY Change -25.0% 20.48% -0.49%
Depreciation, Depletion And Amortization $10.00K $10.00K $0.00
YoY Change -50.0% -50.0% -100.0%
Cash From Operating Activities -$770.0K -$650.0K -$670.0K
YoY Change 22.22% 32.65% 6.35%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 0.000 0.000
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -770.0K -650.0K -670.0K
Cash From Investing Activities 0.000 0.000 0.000
Cash From Financing Activities 0.000 0.000 0.000
Net Change In Cash -770.0K -650.0K -670.0K
YoY Change -420.83% 25.0% 4.69%
FREE CASH FLOW
Cash From Operating Activities -$770.0K -$650.0K -$670.0K
Capital Expenditures $0.00 $0.00 $0.00
Free Cash Flow -$770.0K -$650.0K -$670.0K
YoY Change 22.22% 41.3% 8.06%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2015 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2015
CY2015 dei Document Type
DocumentType
10-K
CY2015Q2 dei Entity Public Float
EntityPublicFloat
4389094
CY2015 dei Amendment Flag
AmendmentFlag
false
CY2015Q4 govx Class Of Warrant Or Right Exercisable
ClassOfWarrantOrRightExercisable
39775491
CY2015Q4 govx Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Exercisable
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisable
0.16
CY2015 dei Document Period End Date
DocumentPeriodEndDate
2015-12-31
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
31950813
CY2013Q1 govx Number Of Warrants Issued During Period
NumberOfWarrantsIssuedDuringPeriod
1766667
CY2014Q4 govx Stock Issued During Period Shares Warrants Exercised
StockIssuedDuringPeriodSharesWarrantsExercised
3176000
CY2014Q4 govx Warrant Exercise Fee Per Share
WarrantExerciseFeePerShare
0.075
CY2015Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
100935
CY2014Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
55616
CY2015Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4055
CY2014Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
52490
CY2015Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
586638
CY2014Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
557703
CY2015Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
32587543
CY2014Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
30823769
CY2013 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
381604
CY2014 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
379103
CY2015 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
67905
CY2015 us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
-15976
CY2014 us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
483448
CY2013 us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
590351
CY2015 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
0
CY2014 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
10000
CY2013 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
10000
CY2015 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
90300000
CY2014 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6600000
CY2013 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
14400000
CY2015Q4 us-gaap Area Of Real Estate Property
AreaOfRealEstateProperty
8400
CY2015Q4 us-gaap Assets
Assets
1331593
CY2014Q4 us-gaap Assets
Assets
1333198
CY2015Q4 us-gaap Assets Current
AssetsCurrent
1236975
CY2014Q4 us-gaap Assets Current
AssetsCurrent
1225495
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1101651
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2513861
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1035925
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1060348
CY2015 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-41303
CY2014 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-1412210
CY2013 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
1477936
CY2012Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.75
CY2013Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.60
CY2013Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.60
CY2013Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.50
CY2015Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.14
CY2015Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
49999998
CY2013Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
2933333
CY2015Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
56442157
CY2013Q1 us-gaap Class Of Warrant Or Right Unissued
ClassOfWarrantOrRightUnissued
1166666
CY2015Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2014Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
90311062
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
31950813
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
31950813
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
31950813
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
31951
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
31951
CY2015Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
5086
CY2014Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
7149
CY2015Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
27136120
CY2014Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
26029092
CY2015Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
27131034
CY2014Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
26021943
CY2015Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2014Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2015Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
23822431
CY2014Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
22806391
CY2015Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
893797
CY2014Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
825896
CY2015Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
2419892
CY2014Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
2396805
CY2015Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
27131034
CY2014Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
26021943
CY2015Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
5086
CY2014Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
7149
CY2015 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
40296
CY2014 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
35567
CY2013 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
43132
CY2014Q4 us-gaap Deposits Assets
DepositsAssets
11010
CY2013Q4 us-gaap Deposits Assets
DepositsAssets
11010
CY2015 us-gaap Depreciation And Amortization
DepreciationAndAmortization
28935
CY2014 us-gaap Depreciation And Amortization
DepreciationAndAmortization
59037
CY2013 us-gaap Depreciation And Amortization
DepreciationAndAmortization
68862
CY2015 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
28935
CY2014 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
69037
CY2013 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
78862
CY2015Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
22000
CY2014Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
78917
CY2015Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
CY2015Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
CY2015Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
CY2015Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
CY2014Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
CY2014Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.03
CY2014Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
CY2014Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.03
CY2015 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.08
CY2014 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.10
CY2013 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.11
CY2014 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-906830
CY2013 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-776881
CY2014 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
878448
CY2013 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
759696
CY2015 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-936936
CY2015 us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
2914
CY2014 us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
1734
CY2015 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
866121
CY2015 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1429731
CY2014 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1807605
CY2013 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1792160
CY2015Q4 us-gaap Grants Receivable
GrantsReceivable
119978
CY2014Q4 us-gaap Grants Receivable
GrantsReceivable
79341
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2015 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2014 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2013 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2014 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-61568
CY2015 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
40637
CY2013 us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
3138
CY2015 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
-67901
CY2014 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
-26648
CY2013 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
-14047
CY2015 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-60033
CY2014 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-125326
CY2013 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-14686
CY2015 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
12146
CY2014 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
934
CY2013 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1268
CY2013 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-125339
CY2015 us-gaap Investment Income Interest
InvestmentIncomeInterest
5465
CY2014 us-gaap Investment Income Interest
InvestmentIncomeInterest
4063
CY2013 us-gaap Investment Income Interest
InvestmentIncomeInterest
4545
CY2015 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
146092
CY2014 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
117084
CY2013 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
117879
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1331593
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1333198
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
126990
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
187023
CY2015 us-gaap Nature Of Operations
NatureOfOperations
<div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px; width: 700px;" border="0" cellpadding="0" cellspacing="0"> <tr> <td style="VERTICAL-ALIGN: top" width="41"> <div style=""><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">1.</div></div></div></td> <td style="VERTICAL-ALIGN: top" width="1192"> <div style=""><div style="display: inline; font-weight: bold;"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Description</div><div style="display: inline; font-weight: bold;"> of Business</div></div></div></div></td> </tr> </table> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></div>&nbsp;</div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">GeoVax Labs, Inc. (&#x201c;GeoVax&#x201d; or the &#x201c;Company&#x201d;), is a clinical-stage biotechnology company developing human vaccines using our novel vaccine platform. Our vaccine delivery technology generates virus-like particles (VLPs) that are effective at eliciting safe and effective immune responses. Our current development programs are focused on vaccines against Human Immunodeficiency Virus (HIV), hemorrhagic fever viruses (Ebola, Marburg, and Lassa) and Zika virus, and for use in cancer immunotherapy. We believe our technology and vaccine development expertise is well-suited for a variety of human infectious diseases and we intend to pursue further expansion of our product pipeline. Our HIV vaccine technology was developed in collaboration with Emory University, the National Institutes of Health (NIH), and the</div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> Centers for Disease Control and Prevention (CDC) and is exclusively licensed to us.</div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> GeoVax is incorporated under the laws of the State of Delaware and our principal offices are located in Smyrna, Georgia (metropolitan Atlanta area). </div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Our vaccine development activities have been, and continue to be, financially supported by the U.S. government. This support has been both in the form of research grants awarded directly to us, as well as indirect support for preclinical animals studies and for the conduct of our human clinical trials.</div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">We operate in a highly regulated and competitive environment. The manufacturing and marketing of pharmaceutical products require approval from, and are subject to, ongoing oversight by the Food and Drug Administration (FDA) in the United States, by the European Medicines Agency (EMA) in the European Union, and by comparable agencies in other countries. Obtaining approval for a new pharmaceutical product is never certain and may take many years and may involve expenditure of substantial resources. Our goal is to build a profitable company by generating income from products we develop and commercialize, either alone or with one or more potential strategic partners. </div></div></div>
CY2015 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2679810
CY2014 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
873400
CY2013 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3259131
CY2015 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-15850
CY2014 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-35503
CY2013 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-86603
CY2015 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2705263
CY2014 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2250107
CY2013 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1694592
CY2015 us-gaap Net Income Loss
NetIncomeLoss
-2689287
CY2014 us-gaap Net Income Loss
NetIncomeLoss
-2733555
CY2013 us-gaap Net Income Loss
NetIncomeLoss
-2284943
CY2015Q1 us-gaap Net Income Loss
NetIncomeLoss
-700454
CY2015Q2 us-gaap Net Income Loss
NetIncomeLoss
-676203
CY2015Q3 us-gaap Net Income Loss
NetIncomeLoss
-619899
CY2015Q4 us-gaap Net Income Loss
NetIncomeLoss
-692731
CY2014Q1 us-gaap Net Income Loss
NetIncomeLoss
-615918
CY2014Q2 us-gaap Net Income Loss
NetIncomeLoss
-679537
CY2014Q3 us-gaap Net Income Loss
NetIncomeLoss
-514515
CY2014Q4 us-gaap Net Income Loss
NetIncomeLoss
-923585
CY2015 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
5465
CY2014 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4063
CY2013 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4545
CY2015 us-gaap Operating Expenses
OperatingExpenses
3122833
CY2014 us-gaap Operating Expenses
OperatingExpenses
3620574
CY2013 us-gaap Operating Expenses
OperatingExpenses
4707038
CY2015 us-gaap Operating Income Loss
OperatingIncomeLoss
-2694752
CY2014 us-gaap Operating Income Loss
OperatingIncomeLoss
-2737618
CY2013 us-gaap Operating Income Loss
OperatingIncomeLoss
-2289488
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
149042
CY2014Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
11010
CY2013Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
11010
CY2015Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
11010
CY2015 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
15850
CY2014 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
35503
CY2013 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
86603
CY2015Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2014Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2015Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2014Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2015Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
56649
CY2014Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
44503
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1705500
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.50
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.41
CY2015 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.11
CY2015 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;">Period to Period Comparisons</div></div></div><div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div><div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Our operating results are expected to fluctuate for the foreseeable future. Therefore, period-to-period comparisons should not be relied upon as predictive of the results for future periods.&nbsp;</div></div></div></div></div></div>
CY2015 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
CY2014 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
873400
CY2013 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1643333
CY2015 us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
2679810
CY2014 us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
CY2013 us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
1615798
CY2014Q4 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
873400
CY2013Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
1060000
CY2013Q2 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
583333
CY2015Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
670246
CY2014Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
654396
CY2015Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
83608
CY2014Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
96693
CY2015 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1693102
CY2014 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1812969
CY2013 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2914878
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-32474927
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-29785640
CY2015 us-gaap Revenue From Grants
RevenueFromGrants
428081
CY2014 us-gaap Revenue From Grants
RevenueFromGrants
882956
CY2013 us-gaap Revenue From Grants
RevenueFromGrants
2417550
CY2015Q1 us-gaap Revenue From Grants
RevenueFromGrants
103424
CY2015Q2 us-gaap Revenue From Grants
RevenueFromGrants
71474
CY2015Q3 us-gaap Revenue From Grants
RevenueFromGrants
93130
CY2015Q4 us-gaap Revenue From Grants
RevenueFromGrants
160053
CY2014Q1 us-gaap Revenue From Grants
RevenueFromGrants
157340
CY2014Q2 us-gaap Revenue From Grants
RevenueFromGrants
180441
CY2014Q3 us-gaap Revenue From Grants
RevenueFromGrants
322086
CY2014Q4 us-gaap Revenue From Grants
RevenueFromGrants
223089
CY2015 us-gaap Share Based Compensation
ShareBasedCompensation
67905
CY2014 us-gaap Share Based Compensation
ShareBasedCompensation
479103
CY2013 us-gaap Share Based Compensation
ShareBasedCompensation
402104
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.9143
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.9488
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.966
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0199
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0198
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.023
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
906761
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.39
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
0
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
0
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
0
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
68000
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
1.50
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
590400
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.09
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.14
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.43
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1183100
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P7Y
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P7Y
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P7Y
CY2015Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y109D
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y109D
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
66622
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
97707
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
165490
CY2013 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
CY2014 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
CY2013 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
20500
CY2014 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
100000
CY2013 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
1615798
CY2015 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
2679810
CY2013 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1643333
CY2014 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
873400
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
1150935
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
2527227
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
1146175
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
1204603
CY2015Q4 us-gaap Unrecorded Unconditional Purchase Obligation Balance Sheet Amount
UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount
72500
CY2015 us-gaap Use Of Estimates
UseOfEstimates
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;">Use of Estimates</div></div></div><div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div><div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may differ from those estimates.</div></div></div></div></div></div>
CY2015 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
31950813
CY2014 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
26645140
CY2013 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
21212327

Files In Submission

Name View Source Status
0001437749-16-027776-index-headers.html Edgar Link pending
0001437749-16-027776-index.html Edgar Link pending
0001437749-16-027776.txt Edgar Link pending
0001437749-16-027776-xbrl.zip Edgar Link pending
b1.jpg Edgar Link pending
ex10-41.htm Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
ex32-2.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
govx-20151231.xml Edgar Link completed
govx-20151231.xsd Edgar Link pending
govx-20151231_cal.xml Edgar Link unprocessable
govx-20151231_def.xml Edgar Link unprocessable
govx-20151231_lab.xml Edgar Link unprocessable
govx-20151231_pre.xml Edgar Link unprocessable
govx20151231_10k.htm Edgar Link pending
govx20151231_10kimg001.gif Edgar Link pending
govx20151231_10kimg001.jpg Edgar Link pending
govx20151231_10kimg002.gif Edgar Link pending
govx20151231_10kimg003.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending